Form 4: Jaguar Health CEO Lisa Conte Reports Stock Transaction

Lisa Conte, CEO of Jaguar Health, reports the acquisition of common stock through the vesting of restricted stock units.

Summary

• Lisa Conte, CEO and President of Jaguar Health, filed a Form 4 on May 21, 2025, reporting a transaction on May 17, 2025.
• The transaction involved the acquisition of 2 shares of common stock due to the vesting of restricted stock units.
• These restricted stock units convert into common stock on a one-for-one basis.
• The reported amount of shares was adjusted to reflect previous reverse stock splits: a 75-for-1 split on January 23, 2023, a 60-for-1 split on May 23, 2024, and a 25-for-1 split on March 18, 2025.
• The restricted stock units vest in three equal annual installments beginning on May 17, 2023.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral.

Positives

• The vesting of restricted stock units indicates a continued alignment of the CEO's interests with those of the shareholders.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders, as it involves a small number of shares.

Key Dates

Keywords

Form 4, Jaguar Health, Lisa Conte, Stock Transaction, Restricted Stock Units, Reverse Stock Split, Beneficial Ownership